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Abstract   
The metabolic regulator fibroblast growth factor 21 (FGF21) has antidiabetic properties in 
animal models of diabetes and obesity. Using quantitative RT-PCR, we here show that the 
hepatic gene expression of FGF21 is regulated by the peroxisome proliferator-activated 
receptor alpha (PPARα). Fasting or treatment of mice with the PPARα agonist Wy-14,643 
induced FGF21 mRNA by 10-fold and 8-fold respectively. In contrast, FGF21 mRNA was 
low in PPARα deficient mice, and fasting or treatment with Wy-14,643 did not induce 
FGF21. Obese ob/ob mice known to have increased PPARα levels, displayed 12-fold 
increased hepatic FGF21 mRNA levels. The potential importance of PPARα for FGF21 
expression also in human liver was shown by Wy-14,643 induction of FGF21 mRNA in 
human primary hepatocytes and PPARα response elements have been identified in both the 
human and mouse FGF21 promoters.  Further studies on the mechanisms of regulation of 
FGF21 by PPARα in humans is of great interest. 
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Introduction 
 
The recently discovered metabolic regulator fibroblast growth factor 21 (FGF21), 
preferentially expressed in the liver [1], has been shown to exert strong antidiabetic and 
triglyceride-lowering effects and also to reduce body weight, when given to animals with diet-
induced or genetic obesity and diabetes, but not when administered to normoglycemic animals 
[2-4]. In spite of these dramatic responses little is yet known about the mechanism of action of 
FGF21 or its regulation apart from a recently described synergistic effect with PPARγ in 
adipose tissue [5]. We recently found that the hepatic gene expression of FGF21 is induced 2-
4 fold following pharmacological or genetic interruption of bile acid circulation, and that 
feeding a sucrose-rich diet induces hepatic FGF21 expression remarkably by 25-fold [6] The 
highest FGF21 mRNA levels were seen in mice deficient in the apical sodium dependent 
transporter (ASBT) receiving a sucrose-rich diet. Interestingly, this diet also strongly reduced 
the high hepatic bile acid synthesis present in ASBT deficient animals, down to levels seen in 
normal wild type (wt) mice.  Furthermore, the increase in hepatic triglycerides following the 
sucrose-rich diet in wt animals was attenuated in ASBT knock out mice [6]. 
The PPARα is a nuclear receptor that has been shown to be a key transcriptional regulator of 
numerous genes involved in lipid metabolism ( for review see [7]). Targeted disruption of the 
PPARα by Lee et al substantiated the role of this receptor in lipid homeostasis [8]. The 
PPARα was shown to be involved in the adaptive response of mice to fasting, since fasted 
PPARα null mice show enhanced lipid accumulation in liver, are hypoglycaemic and have an 
impaired ketone body formation [9, 10]. Since PPARα stimulation also reduces bile acid 
synthesis [11, 12] and plasma triglycerides [11, 13, 14] we speculated that PPARα may be 
involved in the regulation of the expression of hepatic FGF21. To test this hypothesis we 
determined the FGF21 gene expression in liver from PPARα deficient mice and wild-type 
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controls during two different conditions known to stimulate PPARα activity, i.e. treatment 
with the agonist Wy-14,643 and acute fasting.  Our results show that the activation of a 
PPARα response strongly induces the expression of FGF21 in normal mouse liver whereas in 
PPARα deficient mice, having very low basal expression of FGF21, these responses were 
absent. In ob/ob mice that are known to have an increased PPARα activity [15], hepatic basal 
FGF21 mRNA levels were increased 12-fold. Tentative PPARα responsive elements (PPREs) 
were present in the promoter regions of both mouse and human FGF21 genes, and treatment 
of human primary hepatocytes with Wy-14,643 stimulated FGF21 mRNA expression. Our 
results suggest that FGF21 may be a direct transcriptional target of PPARα.  
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Material and methods 
 
Animals and treatment.  Ten to twelve week old wild-type or PPARα-null male mice on a 
pure Sv/129 background (derived from the original colony of mixed background mice [8]) 
and male ob/ob mice obtained from Taconic, Ry, Denmark, were housed in a temperature and 
light-controlled environment. Mice were fed either a control chow diet (Lactamin R36, 
Vadstena, Sweden) or the chow diet containing 0.1% w/w Wy-14,643 (Wyeth14,643, 
Calbiochem-Novabiochem International) for one week. In the fasting experiment, mice were 
fasted for 24 hours and sacrificed at 9.00 am. All mice had access to water ad libitum. 
Animals were sacrificed by CO2 asphyxiation, followed by cervical dislocation and livers 
were excised and snap frozen in liquid nitrogen and subsequently stored at –70°C. The studies 
were approved by the Institutional Animal Care and Use Committee. 
Preparation of Total RNA from mouse liver and Quantitative Real Time PCR. Total RNA was 
prepared from mouse liver using Trizol or QuickPrep® Total RNA extraction kit and DNase 
treated using DNaseI (Promega). cDNA was synthesized from 1µg total RNA using 
SuperscriptIII according to the Manufacturer’s instructions (Invitrogen). Quantitative Real 
time PCR was performed in the ABI 7500 FAST Real-Time PCR System and relative mRNA 
expression was calculated according to the Manufacturer’s instructions (Applied Biosystems). 
TaqMan probes/primers were Assay on Demand; mouse FGF21 Assay ID: Mm00840165_g1, 
human FGF21 Assay ID: Hs00173927_m1. 18S and human acidic ribosomal phosphoprotein 
PO (RPLPO) were used as endogenous controls for mouse and human, respectively (Applied 
Biosystems). 
Culture and Treatment of Human Primary Hepatocytes. Histologically normal liver tissue 
was obtained from a male subject following surgery for liver cancer at GastroCentrum, 
Karolinska University Hospital at Huddinge as part of studies approved by the Ethics 
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Committee at the Karolinska Institutet. Hepatocytes were isolated by a two-step perfusion 
technique, utilizing EGTA and collagenase as described [16]. Cells were cultured in 60 mm 
Petri dishes coated with 200 µL Engelbreth-Holm-Swarm (EHS) matrigel in 3 mL William’s 
E medium with glutamax, supplemented with insulin (2 IU/L), penicillin (100 U/mL), 
streptomycin (100 µg/mL) and gentamycin (85 µg/mL). The medium was changed daily, and 
following four days in culture hepatocytes were incubated with 50 µM Wy-14,643 or vehicle 
(dimethylsulfoxide, DMSO) for 48 hours. The medium was replaced with fresh medium 
containing 50 µM Wy-14,643 after 24 hours. The hepatocytes were collected in Trizol and 
total RNA was isolated, treated with DNase1 (Promega Corp) and stored at –70°C. cDNA 
was synthesized as described above for mouse liver. 
Statistics. The significance of differences between groups in Figures 1 A and B was tested by 
1-way ANOVA followed by post-hoc comparisons according to Tukey using GraphPad Prism 
version 4.03 (GraphPad Software, San Diego California USA).  For the experiments in Figure 
2 and 4, statistical significance was tested by unpaired Student’s t-test (GraphPad Software, 
SanDiego) 
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Results and Discussion 
We first evaluated whether the basal expression of liver FGF21 is reduced in animals devoid 
of PPARα and whether there may be any differences between wt mice and mice devoid of 
PPARα upon treatment with a selective PPARα agonist (Figure 1A). FGF21 expression was  
strongly reduced in PPARα deficient animals and treatment with Wy-14,643 was without 
effect in PPARα-null mice. This was in strong contrast to wt animals where there was a clear 
8-fold increase in the expression of FGF21.  Thus, in line with our hypothesis, the expression 
of FGF21 in this experiment appeared to be completely dependent on the presence of PPARα 
indicating that FGF21 could be a target of PPARα.  Based on the results obtained in this 
pharmacological model, we next explored if FGF21 could be influenced by PPARα under 
more physiological conditions.   
For this purpose, we studied the expression of hepatic FGF21 following 24 hours fasting.  
Previous experiments have shown that PPARα deficient mice have a clearly reduced capacity 
to withstand food deprivation compared to wt mice that appears in part to be due to an 
impaired ability to form glucose and ketone bodies which is vital during prolonged fasting [9, 
10]. We found that the FGF21 mRNA was strongly induced (10-fold) in livers of wt mice 
after 24 hours fasting, whereas in PPARα deficient mice, again expressing very low basal 
levels of FGF21, there was no induction of FGF21 mRNA (Figure 1B).  Therefore under 
physiological conditions that activate PPARα, FGF21 is induced, lending further support to 
the possibility that FGF21 is actually a target gene of PPARα. 
Leptin deficient mice (ob/ob) are known to have activated PPARα function, presumably due 
to increased levels of hepatic fatty acids [15]. We therefore hypothesized that ob/ob mice 
would have an increased hepatic expression of FGF21. mRNA levels of FGF21 were 
therefore measured in the livers of male ob/ob mice and indeed were shown to be elevated 12-
fold (Figure 2). 
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The FGF21 gene is positioned on chromosome 7 and 19 in mouse and human, respectively. 
This region appears well conserved between the species and both the human and the mouse 
FGF21 genes are located in close proximity to the fucosyltransferase 1 (FUT1) gene. As 
shown in figure 3, we identified two putative PPREs in the mouse as well as human FGF21 
promoter regions. These regions are located at -1143 and -2895 upstream of the translation 
start site (ATG) in the mouse gene and at -684 and -2454 in the human gene. Interestingly the 
direct repeat 1 (DR1) site located at -2895 in mouse is in fact a direct repeat 2 (DR2) in 
humans, with only 9 of the 13 base pairs conserved between species.  
The finding of putative PPREs also in the human FGF21 gene prompted us to evaluate 
whether the increased gene expression of FGF21 elicited by Wy-14,643 treatment in mice 
may also occur in human hepatocytes. When human primary hepatocytes were treated with 
Wy-14,643, FGF21 gene expression was clearly induced 3-fold (Figure 4). Although these 
results indicate that PPARα is important also for the hepatic expression of FGF21 in humans, 
further studies remain to be performed to further explore this regulation. It could be 
speculated that this lack of conservation between these sites in human and mouse could 
account for the weaker regulation evident by Wy-14,643 in human hepatocytes compared to 
the regulation of FGF21 in mouse liver and could be due to interaction of other transcription 
factors on the same regulatory element. A DR2 flanked by an AT rich 5’ region in the human 
Rev-erbα promoter was shown to bind the PPARα/RXR heterodimer and was responsible for 
fibrate activation of the human Rev-erbα [17]. Further experiments are therefore required to 
examine if these DR1 or DR2 elements can in fact mediate the PPARα activation of the 
FGF21 genes in mouse or human. 
Important questions to be answered are whether the gene expression of FGF21 is influenced 
by the feeding-fasting transition in humans, as recently reported for FGF19 [18]. It will be of 
particular interest to find out whether pharmacological treatment with PPARα agonists such 
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as fibrates may induce hepatic FGF21 expression and possible secretion of the protein into the 
blood in humans. Such mechanisms may explain some of the positive effects on triglyceride 
and glucose metabolism reported in response to fibrate therapy in humans [14]. Future studies 
are thus needed to establish whether pharmacological treatment with FGF21 protein in 
humans has similar metabolic effects to those previously shown in rodents and monkeys. 
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Figure legends 
Figure 1.  PPARα regulates FGF21 in mouse liver. 
A, Male wild type or PPARα-null mice were treated for one week with 0.1% Wy-
14,643. mRNA levels of FGF21 were measured using real time PCR as described in 
Materials and Methods. mRNA expression is displayed as fold change where the 
expression of the wt group is normalized to 1. Data show mean +/- SEM. n=3. 
B,  Mice were fasted for 24 hours and mRNA levels of FGF21 were measured using 
real time PCR as described in Materials and Methods. mRNA expression is 
displayed as fold change where the expression of the wt group is normalized to 1. 
Data show mean +/- SEM. n=3. 
Figure 2. Comparison of hepatic expression of FGF21 mRNA in ob/ob mice and lean 
controls.  mRNA was measured in the livers of male ob/ob and lean mice. Hepatic 
mRNA expression is displayed as fold change where the expression of the lean 
group is normalized to 1. Data show mean +/- SEM. n=5-6. 
Figure 3. The promoter regions of mouse and human FGF21 genes contain putative 
peroxisome proliferator-response elements (PPREs). The mouse and human FGF21 
promoter regions were aligned using ClustalW. Two putative peroxisome 
proliferator-response elements are shown in boldface and underlined. The 
numbering shown is the position upstream of the translation start site ATG. 
Figure 4. FGF21 expression is increased in human primary hepatocytes by the PPARα agonist 
Wy-14,643 (Wy). Human primary hepatocytes were treated with 50 µM Wy-14,643 
for 48 hours. mRNA expression is displayed as fold change where the expression of 
vehicle-treated cells is normalized to 1. Data show mean +/- SEM. n=6. 
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